Helicobacter pylori (H. pylori) infection is associated with conditions such as gastritis, peptic ulcer, gastric cancer, and certain types of lymphoma. A common presenting complaint among all these H. pylori-related illnesses is dyspepsia. Dr Desmond Wai from the Desmond Wai Liver and Gastrointestinal Diseases Centre, Mount Elizabeth Novena Specialist Centre, Singapore, speaks on the important role general practitioners (GPs) play in recognizing, diagnosing, and treating H. pylori.
Dr. Loey Lung-Yi Mak, Dr. Michael Ka-Shing Cheung, Prof. Man-Fung Yuen, 20170119000000
A 61-year-old man was referred to our centre due to deranged liver function tests (LFT) in 2010. He had enjoyed good past health and had been asymptomatic all along. He worked as a banker and drank small amounts of alcohol on occasions. Upon admission, he was found to be obese with body mass index (BMI) of 36.2 kg/m2. His blood pressure was 173/86 mm Hg. Physical examination was otherwise unremarkable.
A 73-year-old man presented with 1 week’s history of progressive epigastric pain. The pain was dull in nature and the patient reported no vomiting or radiation of pain. On presentation, the patient was found to have a low-grade fever (temperature, 37.8°C). There was no tea-coloured urine. The patient had enjoyed good past health except for a previous surgery for spinal injury.
Long-term use of corticosteroid in the treatment of inflammatory bowel disease (IBD) appears to predispose patients to significant adverse events such as venous thromboembolism (VTE), fragility fractures, and infections, according to a recent retrospective study.
Switching to esomeprazole improves reflux symptoms and quality of life (QoL) in Japanese patients with gastroesophageal reflux disease (GERD) who are refractory to conventional proton pump inhibitors (PPIs), a Japanese study has shown.
Public awareness of the specific alarm symptoms of upper gastrointestinal (GI) cancer are not very prevalent, and healthcare-seeking behaviour regarding the disease remains poor, according to a recent study.
Saccharomyces boulardii aids in lowering Helicobacter pylori colonisation in the gastrointestinal system of asymptomatic primary school children, as reported in a randomised, double-blind, placebo-controlled clinical trial.